What is the current size and annual growth rate of the hemoglobinopathies treatment market?
The hemoglobinopathies treatment market size has grown rapidly in recent years. It will grow from $9.01 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to scientific discoveries, medical advances, patient advocacy, public health awareness, international collaboration and research consortia.
The hemoglobinopathies treatment market size is expected to see strong growth in the next few years. It will grow to $14.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing emphasis on personalized medicine, regulatory support for rare diseases, implementation of prenatal screening programs, genetic counselling services enabled early detection of hemoglobinopathies during pregnancy and expanded adoption of disease-modifying therapies. Major trends in the forecast period include novel drug therapies, cellular therapies, advancements in precision therapeutics, improved diagnostic tools.
Get Your Free Sample of The Global Hemoglobinopathies Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15583&type=smp
What key drivers have fueled the hemoglobinopathies treatment market’s development over the years?
The growing genetic inheritance is expected to propel the growth of the hemoglobinopathies treatment market going forward. Genetic inheritance refers to the method by which characteristics are transferred from parents to offspring through their DNA during sexual and asexual reproduction. Genetic inheritance has grown importance due to improvements in genetic research and technology, which have enhanced understanding of how genetic factors contribute to numerous diseases and ailments, including hemoglobinopathies. Genetic inheritance contributes to the growth of the hemoglobinopathies treatment with improved targeted therapies, personalized medicine, drug development, diagnosis. For instance, in March 2023, Gene People, a UK-based registered charity, the prevalence of genetic conditions in children is estimated that 1 in every 25 children has a genetic problem and 30,000 babies and children are newly diagnosed each year. Therefore, the increasing genetic inheritance is driving the growth of the hemoglobinopathies treatment market.
What is the segmentation for the hemoglobinopathies treatment market?
The hemoglobinopathies treatment market covered in this report is segmented –
1) By Treatment: Stem Cell Therapy, Blood Transfusion
2) By Application: Thalassemia, Sick Cell Anemia
3) By Distribution Channel: Hospital Pharmacy, Online Providers, Drug Stores And Retail Pharmacy
Subsegments:
1) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (Hsct), Gene Therapy For Hemoglobinopathies, Autologous Stem Cell Therapy, Allogeneic Stem Cell Transplantation, Gene Editing Techniques ( Crispr-cas9), Umbilical Cord Blood Stem Cell Therapy, Bone Marrow Transplantation
2) By Blood Transfusion: Regular Blood Transfusion (For Anemia), Exchange Blood Transfusion, Iron Chelation Therapy Post-Transfusion, Red Blood Cell Transfusions, Haploidentical Blood Transfusions, Leukoreduced Blood Transfusion, Emergency Blood Transfusion In Severe Cases
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/hemoglobinopathies-treatment-global-market-report
Who are the most influential companies in the hemoglobinopathies treatment market?
Major companies operating in the hemoglobinopathies treatment market are Pfizer Inc., Sanofi S.A., Novartis AG, Bristol Myers Squibb, Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Pharmacosmos A/S, Alnylam Pharmaceuticals, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Gamida Cell Ltd., Beam Therapeutics, Intellia Therapeutics, Adaptimmune Therapeutics, Orchard Therapeutics plc, Fresenius SE & Co. KGaA, Editas Medicine, Agios Pharmaceuticals Inc., Emmaus Life Sciences Inc., Bluebird Bio Inc., CRISPR Therapeutics AG, Bioverativ Inc., Celgene Corporation, EMI Holding Inc.
What are the top industry trends projected to impact the hemoglobinopathies treatment market?
Major companies operating in the hemoglobinopathies treatment market are developing cell-based gene therapies to provide potentially curative treatments for patients living with these genetic conditions. Cell-based gene therapies for hemoglobinopathies hold promise for correcting the underlying genetic defects, potentially providing long-term or curative effects, reducing symptoms and complications, and advancing treatment options for affected individuals. For instance, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biotech company, launched Casgevy for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia. Casgevy is a cell-based gene therapy that utilizes CRISPR/Cas9 technology to edit patients’ hematopoietic stem cells, increasing the production of fetal hemoglobin to prevent red blood cell sickling. The therapy is a one-time treatment involving the collection, editing, and reinfusion of the patient’s stem cells.
What are the major regional insights for the hemoglobinopathies treatment market, and which region holds the top position?
North America was the largest region in the hemoglobinopathies treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemoglobinopathies treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Hemoglobinopathies Treatment Market Report 2025 Offer?
The hemoglobinopathies treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Hemoglobinopathies treatment refers to the management and care provided to individuals with hemoglobinopathies, which are genetic disorders characterized by abnormal or mutated hemoglobin molecules, such as sickle cell disease and thalassemia. The goal of treatment for hemoglobinopathies is to manage symptoms, prevent complications, and potentially provide curative options to improve patient outcomes and quality of life.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15583
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
